Comparison Study of Insulin Glargine and NPH Insulin

Withdrawn before enrolling · Phase 4

Conditions studied: Diabetes

In brief

This study will compare the safety, effectiveness, and cost of two different types of long-acting insulin.

Key facts

Study ID

NCT01854723

Run by

Providence Health & Services

People needed

0

Starts

2013-04-01

Expected to finish

2015-12-01

Last updated by the study team

2020-03-10

Who can join

Age: any, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult patients at 22 Providence Medical Group primary care clinics
• Diagnosis of type 2 diabetes mellitus
• Currently using greater than 80 units/day of insulin glargine or greater than 1 unit/kg/day of insulin glargine
• Current A1C > 8.5% (within 3 months of randomization)

You may not qualify if…

• Diagnosis of type 1 diabetes mellitus
• Age > 85 years
• Self-reported history of severe hypoglycemia or hypoglycemia unawareness
• Hospice/limited life expectancy
• Current enrollment in Providence Medical Group Medication Assistance Program
• Current use of a GLP1 agonist (i.e., liraglutide, exenatide, exenatide extended-release)
• End stage renal disease (i.e., dialysis or estimated glomerular filtration rate <15 ml/min/1.73m2)
• Cirrhosis
• Unstable coronary artery disease or chronic heart failure (i.e. an exacerbation or hospitalization within 6 months pre-randomization)
• Psychiatric condition that prevents adequate follow-up (i.e., > 3 missed follow-up visits within a 3 month period or persistent non-adherence to dosing or monitoring recommendations)
• Active alcohol or drug abuse
• Inability to provide informed consent

Where it is running

• Providence Medical Group Northeast Clinic — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.